As the presidential election nears -- with just 21 days to go -- questions are swirling about the candidates' health. Over ...

Strong Memorial Hospital, Highland Hospital and other UR Medicine sites paused elective surgeries indefinitely, beginning Oct ...

Medical and political advocacy group ‘Do No Harm’ filed a lawsuit against the University of Washington’s School of Medicine, ...

The Alberta government has made promises to improve the “desperate situation” in family medicine, but no “meaningful change” ...

Texas Children’s Pediatrics earned national recognition for its efforts to improve its physicians’ well-being by reducing the ...

A planned one-day work stoppage set for Tuesday by health care workers at the University of Michigan has been called off ...

Alyssa Bauder was just learning how to read, but she had already memorized the colors of food packaging that spelled danger ...

While the Nobel-winning genome-editing technology CRISPR holds great promise, Duke’s Center for Advanced Genomic Technologies ...

智通财经APP获悉，9月30日，Prime Medicine(PRME.US)宣布与施贵宝(BMY.US)达成战略研发合作和授权协议，共同开发下一代T细胞疗法。这一合作将结合Prime ...

The 2024 Nobel Prize in Medicine was awarded Monday to two American scientists, Victor Ambros and Gary Ruvkun, for their ...

北京时间2024年10月11日00时49分，Editas Medicine, Inc.（EDIT.us）股票出现异动，股价急速下挫5.09%。截至发稿，该股报2.96美元/股，成交量128.566万股， 换手率 1.56%，振幅4.49%。

周五，Leerink Partners维持了对Editas Medicine（NASDAQ:EDIT）的"市场表现"评级，目标价保持在$8.00不变。这一决定是在Editas Medicine最近宣布与DRI Healthcare Trust达成融资协议之后做出的。根据协议条款，Editas将获得$5700万的预付款，以换取来自与VRTX现有许可协议的未来许可费和付款。 该协议授权DRI Heal ...